Merck (MRK) Receivables (2009 - 2026)

Merck (MRK) has reported Receivables for 18 consecutive years, with $12.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 6.06% year-over-year to $12.6 billion in Q2 2026; TTM through Jun 2026 was $12.6 billion, a 6.06% increase from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 14.57% from the prior year.
• Receivables was $12.6 billion for Q2 2026 at Merck, up from $12.2 billion in the prior quarter.
• Over five years, Receivables peaked at $12.6 billion in Q2 2026 and troughed at $10.0 billion in Q4 2022.
• A 5-year average of $11.1 billion and a median of $11.0 billion in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables gained 28.08% in 2022 and retreated 5.07% in 2025, its largest moves.
• Over 5 years, Receivables stood at $10.0 billion in 2022, then rose by 3.9% to $10.3 billion in 2023, then dropped by 0.69% to $10.3 billion in 2024, then rose by 14.57% to $11.8 billion in 2025, then increased by 6.7% to $12.6 billion in 2026.
• The last three Receivables figures came in at $12.6 billion (Q2 2026), $12.2 billion (Q1 2026), and $11.8 billion (Q4 2025), per Business Quant data.